Clinigen Group plc Director/PDMR Shareholding (5835C)
02 October 2018 - 12:29AM
UK Regulatory
TIDMCLIN
RNS Number : 5835C
Clinigen Group plc
01 October 2018
1 October 2018
PDMR SHAREHOLDINGS
Further to the Result of Placing announcement on Thursday 27
September 2018 regarding the placing of 9,467,456 new ordinary
shares (the "Placing Shares"), Clinigen Group plc (AIM: CLIN,
'Clinigen' or the 'Company') announces the following PDMR dealings
in accordance with Article 19 of the Market Abuse Regulation:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Shaun Chilton
------------------------ -------------------------------------
2 Reason for the notification
---------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------ -------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------ -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---------------------------------------------------------------
a) Name Clinigen Group plc
------------------------ -------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
------------------------ -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
------------------------ -------------------------------------
b) Nature of the Director participation in Placing
transaction
------------------------ -------------------------------------
c) Currency GBP
------------------------ -------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
------------------------ ---------------------- -------------
845p per share 7,101
---------------------------------------------------- -------------
e) Aggregated 7,101
information
- Aggregated 845p
volume
- Price GBP60,003.45
- Aggregated
total
------------------------------------------------ ------------------
f) Date of the 1 October 2018
transaction
------------------------ -------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
------------------------ -------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Anne Hyland
------------------------ -------------------------------------
2 Reason for the notification
---------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------ -------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------ -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---------------------------------------------------------------
a) Name Clinigen Group plc
------------------------ -------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
------------------------ -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
------------------------ -------------------------------------
b) Nature of the Director participation in Placing
transaction
------------------------ -------------------------------------
c) Currency GBP
------------------------ -------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
------------------------ ---------------------- -------------
845p per share 4,142
---------------------------------------------------- -------------
e) Aggregated 4,142
information
- Aggregated 845p
volume
- Price GBP34,999.90
- Aggregated
total
------------------------------------------------ ------------------
f) Date of the 1 October 2018
transaction
------------------------ -------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
------------------------ -------------------------------------
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283 495
010
Shaun Chilton, Group Chief Executive
Officer
Martin Abell, Group Chief Financial
Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black / Tom Ballard (Corporate
Broking)
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell
/ Alex Shaw Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. Clinigen acquired Quantum Pharma in
November 2017.
For more information, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFFSIDLLIIT
(END) Dow Jones Newswires
October 01, 2018 10:29 ET (14:29 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024